Luca Ielasi

622 total citations
24 papers, 370 citations indexed

About

Luca Ielasi is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Luca Ielasi has authored 24 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Luca Ielasi's work include Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Cancer Mechanisms and Therapy (6 papers) and Cancer, Lipids, and Metabolism (6 papers). Luca Ielasi is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Cancer Mechanisms and Therapy (6 papers) and Cancer, Lipids, and Metabolism (6 papers). Luca Ielasi collaborates with scholars based in Italy, South Korea and Vietnam. Luca Ielasi's co-authors include Francesco Tovoli, Alessandro Granito, Fabio Piscaglia, Matteo Renzulli, Vito Sansone, Rusi Chen, Francesca Benevento, Bernardo Stefanini, A. Forgione and Sara Marinelli and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Hepatology and Annals of Oncology.

In The Last Decade

Luca Ielasi

21 papers receiving 370 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Luca Ielasi 231 102 96 92 85 24 370
Hilda Wong 219 0.9× 120 1.2× 89 0.9× 94 1.0× 89 1.0× 18 433
Ru-Hai Zou 176 0.8× 65 0.6× 96 1.0× 59 0.6× 68 0.8× 15 361
Takashi Hisai 252 1.1× 128 1.3× 36 0.4× 74 0.8× 66 0.8× 6 357
Maria Aurelia Barbera 104 0.5× 134 1.3× 80 0.8× 70 0.8× 53 0.6× 19 284
Chiara Cristofori 387 1.7× 107 1.0× 148 1.5× 83 0.9× 81 1.0× 14 547
Guoliang Shao 375 1.6× 155 1.5× 87 0.9× 138 1.5× 86 1.0× 34 553
P. Merle 195 0.8× 60 0.6× 60 0.6× 44 0.5× 79 0.9× 5 333
Diyu Huang 123 0.5× 136 1.3× 170 1.8× 86 0.9× 96 1.1× 27 466
Juxian Sun 384 1.7× 82 0.8× 161 1.7× 105 1.1× 111 1.3× 45 546
Marco Sanduzzi‐Zamparelli 268 1.2× 78 0.8× 60 0.6× 40 0.4× 61 0.7× 30 424

Countries citing papers authored by Luca Ielasi

Since Specialization
Citations

This map shows the geographic impact of Luca Ielasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Ielasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Ielasi more than expected).

Fields of papers citing papers by Luca Ielasi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Ielasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Ielasi. The network helps show where Luca Ielasi may publish in the future.

Co-authorship network of co-authors of Luca Ielasi

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Ielasi. A scholar is included among the top collaborators of Luca Ielasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Ielasi. Luca Ielasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ielasi, Luca, Bernardo Stefanini, Fabio Conti, et al.. (2024). Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy. Current Oncology. 31(1). 547–557. 2 indexed citations
2.
Stefanini, Bernardo, et al.. (2024). Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?. SHILAP Revista de lepidopterología. 24(1). 23–32. 3 indexed citations
3.
4.
5.
Stefanini, Bernardo, et al.. (2023). TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy. 23(3). 279–291. 74 indexed citations
6.
Ielasi, Luca, Francesco Tovoli, Bernardo Stefanini, et al.. (2023). Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers. 15(5). 1523–1523. 4 indexed citations
7.
Ielasi, Luca, Bernardo Stefanini, Fabio Piscaglia, Alessandro Granito, & Francesco Tovoli. (2023). A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival. Gastroenterology Insights. 14(1). 38–44. 1 indexed citations
8.
Ielasi, Luca, et al.. (2023). Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia. World Journal of Hepatology. 15(5). 675–687. 2 indexed citations
9.
Chen, Rusi, et al.. (2023). Donafenib in hepatocellular carcinoma. Drugs of today. 59(2). 83–90. 16 indexed citations
10.
Monaco, Giovanni, et al.. (2023). Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art. World Journal of Gastroenterology. 29(33). 4962–4974. 7 indexed citations
11.
Tovoli, Francesco, Vito Sansone, Massimo Iavarone, et al.. (2022). Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments. Transplantation. 107(1). 156–161. 8 indexed citations
12.
Ielasi, Luca, Francesco Tovoli, Raffaella Tortora, et al.. (2021). Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. Cancers. 13(24). 6376–6376. 14 indexed citations
13.
Granito, Alessandro, A. Forgione, Sara Marinelli, et al.. (2021). Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology. 14. 1088199935–1088199935. 100 indexed citations
14.
Ielasi, Luca, et al.. (2021). An update on atezolizumab for hepatocellular carcinoma. Drugs of today. 57(6). 365–365. 1 indexed citations
15.
Sansone, Vito, Francesco Tovoli, Andrea Casadei‐Gardini, et al.. (2021). Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clinical and Translational Gastroenterology. 12(1). e00286–e00286. 12 indexed citations
16.
Ielasi, Luca, et al.. (2020). Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery. SHILAP Revista de lepidopterología. 7(3). HEP24–HEP24. 3 indexed citations
17.
Marisi, Giorgia, Vincenzo Dadduzio, Luca Ielasi, et al.. (2019). Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. Annals of Oncology. 30. iv113–iv113. 1 indexed citations
18.
Ielasi, Luca, Francesco Tovoli, & Fabio Piscaglia. (2019). Lenvatinib mesylate to treat hepatocellular carcinoma. Drugs of today. 55(5). 305–305. 12 indexed citations
19.
Tovoli, Francesco, Luca Ielasi, Andrea Casadei‐Gardini, et al.. (2019). Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. Journal of Hepatology. 71(6). 1175–1183. 61 indexed citations
20.
Ielasi, Luca, Vito Sansone, Alessandro Granito, et al.. (2018). An update of treatments of hepatocellular carcinoma in patientsrefractory to sorafenib. Drugs of today. 54(10). 615–615. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hilda Wong Breakdown of academic impact, for papers by Ru-Hai Zou Breakdown of academic impact, for papers by Takashi Hisai Breakdown of academic impact, for papers by Maria Aurelia Barbera Breakdown of academic impact, for papers by Chiara Cristofori Breakdown of academic impact, for papers by Guoliang Shao Breakdown of academic impact, for papers by P. Merle Breakdown of academic impact, for papers by Diyu Huang Breakdown of academic impact, for papers by Juxian Sun Breakdown of academic impact, for papers by Marco Sanduzzi‐Zamparelli
Rankless by CCL
2026